Unlocking the Next
Chapter of Kidney Care
Meet the Expert Series: Video On Demand-Prof. Per Henrik Groop
Should we consider using SGLT2i among the A1 and A2 Patients with CKD based on Empa Kidney? How should we look at the eGFR slope decline of Empagliflozin in EMPA Kidney based on albuminuric subgroups A1 A2 A3?
Related Videos
1:30
EK22||Should there be a safety concern for the eGFR dip in initiating SGLT2i in CKD patients?
1:27
EK22||Should SGLT2i be discontinued if eGFR levels fall below 20ml/min?
3:22
EK22||What is unique of the EMPA Kidney Study Design and its difference in the previously available CKD trials published / How would you Characterize the CKD Patient population in EMPAKIDNEY in relation to previous CKD Trials?
2:22
EK22||What is the significance of the primary endpoint of Kidney Disease Progression and CV Death regardless of Diabetes Status as an outcome and what does this mean for Physicians and CKD patients?
2:56
EK22||There seems to be equivocal or no benefit in kidney disease progression in patients with A1, and A2 Albuminuria subgroups in EMPAKIDNEY. What's your point of view in these results?
2:12
EK22||To which patients should we give Empagliflozin? For which patient co morbidities should we consider early initiation of SGLT2i to optimize organ protective benefits?
2:08
EK22||How would you explain mechanistically How SGLT2i works as treatment for CKD?
01:22
EK22||What are your thoughts around why there was late separation between Empagliflozin and Placebo in the Kaplan Meier curve for the Primary Endpoint in EMPAKIDNEY
02:52
EK22||How should we look at the eGFR slope decline of Empagliflozin in EMPA Kidney based on albuminuric subgroups A1 A2 A3?
6:42
EK22||Hypertensive, Newly Diagnosed with CKD not on SGLT2i, what is your usual approach managing this patient based on your Practice
1:51
EK22||When there's newly diagnosed CKD patient with hypertension, which class of drug would you consider as first line treatment? What is the usual interval between different treatments?
08:35
EK22||How can we improve Shared Care Approaches for Specialist and Primary Care Physicians in managing patients with CKD and Cardio Renal and Metabolic conditions for better patient care?
Document ID: SC-ASK-00679